---
title: "Oncolytics Biotech Inc. (ONCY.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ONCY.US/overview.md"
symbol: "ONCY.US"
name: "Oncolytics Biotech Inc."
parent: "https://longbridge.com/en/quote/ONCY.US.md"
datetime: "2026-04-15T09:16:53.138Z"
locales:
  - [en](https://longbridge.com/en/quote/ONCY.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ONCY.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ONCY.US/overview.md)
---

# Oncolytics Biotech Inc. (ONCY.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 322 11th Avenue SW, Suite 804, Calgary, Alberta, Canada |
| Website | [oncolyticsbiotech.com](https://oncolyticsbiotech.com) |

## Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc.

## Key Executives

| Name | Title |
|------|-------|
| Jared Kelly | CEO & Director |
| Wayne F. Pisano | Chairman of the Board |
| Kirk J. Look | Chief Financial Officer |
| Thomas C. Heineman | Chief Medical Officer |
| John McAdory | Executive VP of Strategy & Operations |
| Allison Hagerman | Chief Technology Officer |
| Angela Frances Holtham | Independent Director |
| Deborah M. Brown | Independent Director |
| Jonathan M. N. Rigby | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Bernd Robert Seizinger | 0.49% | 2026-02-12 |
| Wayne F. Pisano | 0.42% | 2026-02-12 |
| Morgan Stanley | 0.37% | 2025-12-31 |
| Sandbox Financial Partners, LLC | 0.34% | 2026-03-31 |
| Kirk J. Look | 0.25% | 2026-02-12 |
| Thomas C. Heineman | 0.24% | 2026-02-12 |
| Marshall Wace LLP | 0.23% | 2025-12-31 |
| Seeds Investor LLC | 0.22% | 2025-12-31 |
| International Assets Investment Management, LLC | 0.18% | 2025-12-31 |
| Angela Frances Holtham | 0.16% | 2026-01-01 |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**